94. Primary sclerosing cholangitis Clinical trials / Disease details


Clinical trials : 142 Drugs : 113 - (DrugBank : 37) / Drug target genes : 19 - Drug target pathways : 139

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02239211
(ClinicalTrials.gov)
September 8, 20154/9/2014A Trial of BTT1023 in Patients With Primary Sclerosing CholangitisA Single Arm, Two-stage, Multi-centre, Phase II Clinical Trial Investigating the Safety and Activity of the Use of BTT1023 Targeting Vascular Adhesion Protein (VAP-1), in the Treatment of Patients With Primary Sclerosing Cholangitis (PSC).Primary Sclerosing CholangitisDrug: BTT1023University of BirminghamBiotie Therapies Corp.;University Hospital Birmingham;National Institute for Health Research, United KingdomCompleted18 Years75 YearsAll23Phase 2United Kingdom
2EUCTR2014-002393-37-GB
(EUCTR)
06/01/201519/11/2014A clinical trial investigating the use of BTT1023 in patients with PSCA single arm, two-stage, multi-centre, phase II clinical trial investigating the safety and activity of the use of BTT1023, a human monoclonal antibody targeting vascular adhesion protein (VAP-1), in the treatment of patients with primary sclerosing cholangitis (PSC) - BUTEO: A clinical trial of BTT1023 in patients with PSC Primary Sclerosing Cholangitis (PSC)
MedDRA version: 20.1;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 100000004871;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: BTT1023 IV Infusion 20 mg/mL, 5 mL Drug Product
Product Code: BTT1023
University of BirminghamNULLNot RecruitingFemale: yes
Male: yes
59Phase 2United Kingdom